Related Experiment Videos

The effect of aldosterone antagonists for ventricular arrhythmia: a meta-analysis

Jiafu Wei1, Juan Ni, Dejia Huang

  • 1Cardiology Department, West China Second University Hospital, Sichuan University, Sichuan, China.

Clinical Cardiology
|September 16, 2010
PubMed

Insights

Aldosterone antagonists (AAs) significantly reduce sudden cardiac death (SCD) risk in heart failure (HF) patients. These AAs also decrease ventricular arrhythmias, including ventricular tachycardia and premature complexes.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Sudden cardiac death (SCD), often caused by ventricular arrhythmia (VA), is a major concern in heart failure (HF).
  • Aldosterone antagonists (AAs) are known to reduce SCD in HF patients and may possess antiarrhythmic properties.

Purpose of the Study:

  • To evaluate the effect of aldosterone antagonists (AAs) on ventricular arrhythmia (VA) in patients with heart failure (HF) or coronary artery disease.

Main Methods:

  • A systematic review of randomized controlled trials was conducted.
  • Searches were performed in major databases including Cochrane Central Register of Controlled Trials, PubMed, and others.
  • Data from 7 trials involving 8635 patients were extracted and analyzed.

Main Results:

  • Aldosterone antagonists (AAs) reduced the risk of sudden cardiac death (SCD) by 21% in heart failure (HF) patients.
  • A significant reduction in ventricular premature complexes was observed (mean difference 705 ± 646 episodes per 24 hours).
  • The risk of ventricular tachycardia was reduced by 72% with AA use.

Conclusions:

  • Additional administration of aldosterone antagonists (AAs) provides significant benefits for heart failure (HF) patients.
  • AAs demonstrate efficacy in reducing the risk of sudden cardiac death (SCD).
  • AAs may also be effective in decreasing episodes of ventricular premature complexes and ventricular tachycardia.
Abstract

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...